Data in Excess: A Confluence of Oncology/Hematology Conferences Presents Key Clinical Research

The start of a new year naturally lends itself to reflecting on the close of the last. Considering the excess of data that poured out from the oncology/hematology conferences of December 2022, including the 64th American Society of Hematology (ASH) Annual Meeting & Exposition and the 2022 San Antonio Breast Cancer Symposium (SABCS), January 2023 is as good a time as any to sift through those data to determine what will and won’t be applicable and/or beneficial to consider in the new year. Pharmacy Times^® attended both ASH and SABCS in 2022 (alongside the 2022 American Society of Health-System Pharmacists Midyear Clinical Meeting and Exhibition around the same time) and began that sifting process for our readers to, hopefully, save them some time engaging in similar efforts.

In this special January issue covering ASH and SABCS, we have divided the publication by conference. Each conference section begins with highlights from Pharmacy Times Oncology Edition^™ editorial advisory board member Douglas Braun, PharmD, CSP, RPh, senior pharmacy director at American Oncology Network, LLC. Braun details in each article on pages 14 and 32 clinical trial results and drug pipeline updates of note from the conferences that stand out as potentially impacting clinical practice in the New Year and beyond.

For each conference, the issue also contains deeper dives into trial data, such as phase 3 interim results presented at SABCS from the monarchE trial (NCT03155997) assessing adjuvant abemaciclib (Verzenio; Eli Lilly and Company) plus endocrine therapy to treat hormone receptor–positive, HER2-negative, node-positive, high-risk early breast cancer on page 36. We also cover phase 1 trial (NCT04830137) findings presented at ASH assessing NX-2127 (Nurix Therapeutics) in adults with double-refractory and emerging triple-refractory chronic lymphocytic leukemia on page 28.

Additionally, this issue contains insights from coauthors Samvel Nazaretyan, a PharmD student; Amir Ali, PharmD, BCOP; and George Yaghmour, MD, on results from a retrospective analysis presented at ASH investigating FMS-like tyrosine 3 inhibitors to treat patients with acute myeloid leukemia post hematopoietic stem cell transplant on page 20.

Also, on page 22, Pharmacy Times^® interviews Richard T. Maziarz, MD, a professor of medicine and medical director of the adult Oregon Health & Science University (OHSU) stem cell transplant program at OHSU Knight Cancer Institute, about his research presented at ASH. Maziarz aimed to estimate the average medical costs of allogeneic hematopoietic cell transplantation throughout a patient’s lifetime and the net savings and value associated with reducing complications.

We hope you enjoy this overview of December’s outpour of data and drug pipeline information in this single issue. We will attempt this feat again in a special July 2023 issue covering the American Society of Clinical Oncology Annual Meeting, which takes place in June this year.